Background
Patients with cirrhosis are prone to mental and psychological problems. However, data on mental and psychological problems in patients with cirrhosis during the coronavirus disease 2019 (COVID-19) pandemic are lacking. Therefore, we aimed to investigate the prevalence and risk factors of anxiety and depression in this population.
Methods
The Patient Health Questionnaire-9 Scale and Generalized Anxiety Disorder 7-item scale were used to collect mental health data in this cross-sectional study. Multivariate logistic regression analysis was performed to evaluate the relevant influencing factors of anxiety and depression.
Results
The prevalence rates of anxiety and depression in patients with cirrhosis were 21.3% and 29.9%, respectively. Anxiety risk was higher among patients with cirrhosis who had significant abdominal pain and treatment interruption; COVID-19 vaccination was associated with anxiety reduction as a protective factor. Depression risk was higher among patients with cirrhosis for > 10 years, significant abdominal pain within one week, and treatment interruption. Course of cirrhosis of 5–10 years and COVID-19 vaccination were associated with the reduction of depression as protective factors.
Conclusion
COVID-19 vaccination is a protective factor for both depression and anxiety. Our findings may help healthcare professionals to develop appropriate treatment strategies and timely psychological interventions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.